AAPS PharmSci 360 2026:Thermo Fisher 谈口服固体制剂 AI 工具、监管证据与数据准备
AAPS PharmSci 360 2026: AI Tools, Regulations, and Preparedness
Thermo Fisher Scientific 科学与创新高级总监 Sanjay Konagurthu 在 AAPS PharmSci 360 2026 上表示,口服固体制剂 AI 策略成败取决于配方、分析和数据科学三方的数据协作。
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, spoke with PharmTech at AAPS PharmSci 360 2026 about what goes into building a successful artificial intelligence (AI) strategy for oral drug product development. He also provided insight into how regulators expect AI evidence to be handled, and why data remains the biggest obstacle to the adoption of AI.
Success depends on well-structured access to data and close collaboration across three groups, according to Konagurthu. Formulation scientists design the dosage form, weighing excipient choice, API properties, and unit operations. Analytical scientists characterize the formulation’s physical and chemical attributes. Data scientists turn that data into models that can be validated, he explained.
On regulation, he noted that AI evidence supporting drug product quality or other regulatory decisions should be fit for purpose and backed by an appropriate level of validation. He pointed to the FDA’s recent nonbinding draft guidance and to shared FDA and European Medicines Agency principles emphasizing clear intended use, sound data management and governance, performance assessment, human oversight, and lifecycle management. Sponsors using these tools, he said, should keep an auditable record of data, model versions, validation results, limitations, human review, and any postvalidation changes.
Konagurthu said he expects near-term progress in optimizing the manufacturability and dissolution of tablets and capsules, and in formulation screening for poorly soluble small molecules through platforms such as Thermo Fisher’s Quadrant 2. These platforms produce measurable outcomes that can guide the next experiment. Predicting clinical exposure from an API’s structure and properties remains the “holy grail,” and his team is working on it. To prepare, he advised companies to standardize formulation and dissolution data and connect lab records to process and material attributes.
Data access is still the biggest hurdle, he stressed. In his view, well-organized data are 80% to 90% of the task, with model building and validation coming later. Although models are advancing rapidly, he said that he expects the industry to make real progress on data access within 2 to 5 years.
Konagurthu gave the keynote presentation, 3D Printing: Driving Digital Transformation from Dosage Form Design to Product Development and Manufacturing, at AAPS PharmSci 360, which is being held from October 25-28 in New Orleans.
About the Speaker
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific is a chemical engineer with more than 25 years of industry experience. He specializes in small-molecule oral drug delivery, including solubility and bioavailability enhancement, spray drying, hot-melt extrusion, nanotechnology, and modified- and controlled-release dosage forms, from early development through commercialization. He also leads Thermo Fisher’s predictive modeling and simulation team, which applies modeling to solubility enhancement, predictive stability, packaging shelf-life simulation, process development, and pharmacokinetics.
Related to this article
November 13th, 2026
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
November 9th, 2026
CPHI Award winner, Pauline van der Wijst-Janssen, PhD, product development manager and global technical lead at DFE Pharma, explains excipient variability and excipients’ role in continuous manufacturing.
November 9th, 2026
Pauline van der Wijst-Janssen, PhD, of DFE Pharma, won the CPHI Pharma Award for Future Leader. In this interview with PharmTech, she provides advice for scientists looking to advance to leadership roles.
November 6th, 2026
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains how her team managed the study’s strict −80 °C handling requirement, quality release, and site readiness, and how the Almac Adapt approach can apply beyond this program.
November 5th, 2026
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
November 5th, 2026
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
November 13th, 2026
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
November 12th, 2026
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
来源:PharmTech Quality Systems · pharmtech.com





